Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000266268
Ethics application status
Approved
Date submitted
17/02/2009
Date registered
14/05/2009
Date last updated
5/07/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
The IDEAL Study: a clinical trial of the timing of kidney dialysis initiation on survival in subjects with chronic kidney disease.
Scientific title
Initiating Dialysis Early and Late (IDEAL) Study. A study reviewing the effect of the timing of dialysis initiation on survival in subjects with chronic kidney disease.
Secondary ID [1] 251670 0
Trial first registered as a publication of the trial protocol in March 2004: Peritoneal Dialysis International, 2004; 24: 176-181.
Universal Trial Number (UTN)
Trial acronym
IDEAL Study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney disease 4344 0
Cardiac disease 4345 0
Nutrition 4346 0
Condition category
Condition code
Renal and Urogenital 4587 4587 0 0
Kidney disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Subjects randomized to the Early dialysis initiation: commence dialysis as soon as possible with a target glomerular filtration rate (GFR) of 10-14 ml/min/1.73m^2.
Dialysis type and regimen used (haemodialysis or peritoneal dialysis) is determined by the caring renal physician.
Intervention code [1] 4077 0
Treatment: Devices
Comparator / control treatment
Subjects randomized to the Late dialysis initiation: delay the commencement of dialysis until their GFR is between 5-7 ml/min/1.73m^2.
Dialysis type and regimen used (haemodialysis or peritoneal dialysis) is determined by the caring renal physician.
Control group
Active

Outcomes
Primary outcome [1] 5463 0
All cause mortality
Timepoint [1] 5463 0
At the end of the trial. 800 patients will be followed every 3 months for a minimum of 3 years post randomization.
Secondary outcome [1] 9202 0
Quality of life as measured by using the following research tools:
Health Utilities Index III (HUI III), a multi-attribute generic instrument for measuring quality of life;
Assessment of Quality of Life (AQoL), another multi-attribute generic instrument for measuring quality of life;
Kidney Disease Quality of Life (KDQOL), a disease-specific instrument for measuring quality of life.
Timepoint [1] 9202 0
Health Utilities Index III (HUI III) is completed by each patient at baseline and every three months thereafter;
Assessment of Quality of Life (AQoL) is also completed by each patient at baseline and every three months thereafter;
Kidney Disease Quality of Life (KDQOL) is completed by each patient at baseline and every 12 months thereafter.
Secondary outcome [2] 9203 0
Cost of treatment:
Health Services Utilisation (HSU), an instrument used to collect data on use of hospital resources; and
Patient Diary, an instrument used to collect data on use of community resources.
A separate review of the cost of dialysis in Australia and New Zealand has also been performed and comparisons will also be made with other already published data.
Timepoint [2] 9203 0
Health Services Utilisation (HSU) is completed for each patient every 3 months after baseline (but not at baseline). This form is completed by the study nurse from the patient's hospital records; and
Patient Diary is completed by each patient each month.
Secondary outcome [3] 9204 0
Cardiac echo changes that will be studied include:
a) left ventricular mass;
b) systolic function;
c) diastolic function; and
d) myocardial fibrosis.
Timepoint [3] 9204 0
Cardiac echo changes will be reviewed in each subject at 0, 6 and 12 months and also just prior to the commencement of dialysis in patients randomized to the late start group.
Secondary outcome [4] 9205 0
Nutrition will be assessed using the following measures:
a) Total body nitrogen assessment using prompt neutron activation analysis;
b) Subjective global assessment: a clinical nutrition score;
c) Bioelectrical impedance monitoring; and
c) Serum albumin measurement.
Timepoint [4] 9205 0
At baseline and then every 12 months for 3 years.

Eligibility
Key inclusion criteria
Age greater than 18 years. Progressive chronic kidney disease. GFR between 10-20ml/min/1.73m^2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Significant cancer. Planned live renal transplant in the next 12 months.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible patients are consented and have baseline data collected to confirm inclusion criteria. Central computerized randomization with allocation concealment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomization with stratification for Diabetes, Center and Planned Dialysis Modality.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/07/2000
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
800
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 1575 0
New Zealand
State/province [1] 1575 0

Funding & Sponsors
Funding source category [1] 4516 0
Government body
Name [1] 4516 0
National health and medical research council (NHMRC)
Country [1] 4516 0
Australia
Funding source category [2] 4517 0
Government body
Name [2] 4517 0
Australian Health Ministers' Advisory Council (AHMAC)
Country [2] 4517 0
Australia
Funding source category [3] 4518 0
Commercial sector/Industry
Name [3] 4518 0
Baxter Australia
Country [3] 4518 0
Australia
Funding source category [4] 4519 0
Other Collaborative groups
Name [4] 4519 0
Don and Lorraine Jacquot Fellowship
Australian and New Zealand Society of Nephrology
Country [4] 4519 0
Australia
Funding source category [5] 4520 0
Commercial sector/Industry
Name [5] 4520 0
Amgen Australia
Country [5] 4520 0
Australia
Funding source category [6] 4521 0
Government body
Name [6] 4521 0
Health Funding Authority New Zealand (Te Mana Putea Hauora O Aotearoa)
Country [6] 4521 0
New Zealand
Funding source category [7] 4522 0
Charities/Societies/Foundations
Name [7] 4522 0
National Heart Foundation - Australia
Country [7] 4522 0
Australia
Funding source category [8] 4523 0
Charities/Societies/Foundations
Name [8] 4523 0
National Heart Foundation - New Zealand
Country [8] 4523 0
New Zealand
Primary sponsor type
Other Collaborative groups
Name
Steering Committee of the IDEAL Study
Address
C/O Dr Bruce Cooper
Department of Renal Medicine
Royal North Shore Hospital
St Leonards NSW 2065
Country
Australia
Secondary sponsor category [1] 4084 0
None
Name [1] 4084 0
Address [1] 4084 0
Country [1] 4084 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 6576 0
Northern Sydney and Central Coast Area Health Service
Ethics committee address [1] 6576 0
Ethics committee country [1] 6576 0
Australia
Date submitted for ethics approval [1] 6576 0
Approval date [1] 6576 0
Ethics approval number [1] 6576 0
0407-156M

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 29301 0
Address 29301 0
Country 29301 0
Phone 29301 0
Fax 29301 0
Email 29301 0
Contact person for public queries
Name 12548 0
Dr Bruce A Cooper
Address 12548 0
Department of Renal Medicine
Royal North Shore Hospital
St Leonards NSW 2065
Country 12548 0
Australia
Phone 12548 0
+61 2 9926 8257
Fax 12548 0
+61 2 9926 5484
Email 12548 0
[email protected]
Contact person for scientific queries
Name 3476 0
Dr Bruce A Cooper
Address 3476 0
Department of Renal Medicine
Royal North Shore Hospital
St Leonards NSW 2065
Country 3476 0
Australia
Phone 3476 0
+61 2 9926 8257
Fax 3476 0
+61 2 9926 5484
Email 3476 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIEffect of Timing of Dialysis Commencement on Clinical Outcomes of Patients with Planned Initiation of Peritoneal Dialysis in the Ideal Trial2012https://doi.org/10.3747/pdi.2012.00046
N.B. These documents automatically identified may not have been verified by the study sponsor.